Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMoving up to 7.5mg Mounjaro is a clinical decision, not a calendar one. Whether the 5mg dose has been tolerable and your weight loss has plateaued, or you're simply wondering what comes next, the honest answer is: your prescriber reviews your response at each stage before any dose change is made. Tirzepatide's titration schedule exists precisely because the right dose is individual, not automatic. These are prescription-only medicines, and suitability for any increase is assessed by a GPhC-registered Independent Prescriber who reviews your full picture, not just the number on the scale.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro titration schedule, as set out in the prescribing information on the Electronic Medicines Compendium, works in roughly four-week steps: 2.5mg to settle in, 5mg to begin therapeutic effect, and 7.5mg when there is clinical reason to go further. That reason is usually a combination of two things: the current dose is being tolerated reasonably well, and the weight response is either slowing or less than expected. Neither factor alone is enough. Someone losing weight steadily at 5mg with mild nausea that has not yet resolved is not a straightforward candidate for an increase, even if the calendar says four weeks have passed.
It is a question our prescribers hear most weeks: "I've been on 5mg for a month, should I go up?" The answer depends on what that month actually looked like. If appetite suppression feels steady, gastrointestinal symptoms have largely settled, and weight loss has stalled, a move to 7.5mg is a reasonable next step to discuss. If you are still experiencing significant nausea or digestive disruption, your body may simply need more time to adapt at the current dose before any increase is considered. There is no clinical benefit in escalating too fast, and doing so tends to worsen side effects without improving results. If you are still at the previous stage and wondering whether to move up to 5mg Mounjaro, that question is worth settling first before thinking about any further increases. You can read more about the broader considerations around going up a dose on Mounjaro if you are weighing that decision more generally.
A clinical review before a dose increase is not a formality. At nume, every repeat order including any dose step-up is reviewed by a prescriber who checks evidence of your current dose and your current weight. That means real verification, not a self-reported form submitted in thirty seconds.
Your prescriber will be thinking about several things. First, tolerability: are the most common side effects, including nausea, loose stools, constipation, reflux and fatigue, at a level that a higher dose is unlikely to push into something unmanageable? Second, response: is there meaningful weight loss underway, or has the 5mg dose reached the limit of its effect for you? Third, your baseline health: conditions such as a history of pancreatitis or certain gastrointestinal problems require particular care at every stage of titration. The NHS guidance on tirzepatide sets out the clinical context clearly and is worth reading alongside whatever your own prescriber advises.
If you have recently started experiencing any new or worsening symptoms at 5mg, that is worth raising before assuming a dose increase is the answer. Sometimes the right response is to hold, not advance.
Tirzepatide works as a dual GIP and GLP-1 receptor agonist, activating two hormonal pathways that together reduce appetite, slow how quickly the stomach empties and improve how the body manages blood sugar. At higher doses, both pathways are engaged more strongly, which is why the evidence from SURMOUNT-1 shows progressively greater average weight loss as doses increase toward 15mg. Moving to 7.5mg is moving into the range where, for many people, the appetite-suppressing effect becomes more noticeable day to day.
That stronger effect is also why side effects can intensify with each step. Nausea, in particular, tends to peak in the first week or two after an increase before settling again. Eating smaller portions, avoiding rich or fatty foods and staying well hydrated all help during this adjustment window. For a fuller look at what the titration journey looks like across all doses, the Mounjaro weekly dose page covers the schedule in more detail. The 5mg Mounjaro page is also useful if you want to compare what the previous dose typically delivers before committing to a change.
Staying at 5mg for longer than the minimum four weeks is not a failure of the treatment or of you. Some people find that the 5mg dose continues to produce steady weight loss well beyond the initial month, and in that case a prescriber may reasonably suggest holding before escalating. The aim is the highest dose that works for you with acceptable tolerability, not the highest dose available.
If you are wondering whether the overall cost picture changes as you move through the dose steps, the Mounjaro pricing page gives an honest account of how private treatment is structured. For context on the full Mounjaro treatment pathway, including eligibility and what to expect from start to finish, that pillar page covers everything in one place. When you are ready to have the dose question reviewed properly, starting a free consultation is how to put it in front of a real prescriber rather than trying to answer it yourself.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.